Skip to content

In the BioHarmony Drug Report Database

Tazemetostat

Tazverik (tazemetostat) is a small molecule pharmaceutical. Tazemetostat was first approved as Tazverik on 2020-01-23. The pharmaceutical is active against histone-lysine N-methyltransferase EZH2. Tazverik's patents are valid until 2035-12-19 (FDA).
Trade Name Tazverik
Common Name Tazemetostat
Indication
Drug Class Enzyme inhibitors
Tazemetostat
Get full access now